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Treatment with the protein kinase C activator 12-O-
tetradecanoylphorbol 12-acetate (TPA) enables radia-
tion-resistant LNCaP human prostate cancer cells to
undergo radiation-induced apoptosis, mediated via ac-
tivation of the enzyme ceramide synthase (CS) and de
novo synthesis of the sphingolipid ceramide (Garzotto,
M., Haimovitz-Friedman, A., Liao, W. C., White-Jones, M.,
Huryk, R., Heston, D. W. W., Cardon-Cardo, C., Kolesnick,
R., and Fuks, Z. (1999) Cancer Res. 59, 5194–5201). Here,
we show that TPA functions to decrease the cellular
level of the ATM (ataxia telangiectasiamutated) protein,
known to repress CS activation (Liao, W.-C., Haimovitz-
Friedman, A., Persaud, R., McLoughlin, M., Ehleiter, D.,
Zhang, N., Gatei, M., Lavin, M., Kolesnick, R., and Fuks,
Z. (1999) J. Biol. Chem. 274, 17908–17917). Gel shift anal-
ysis in LNCaP and CWR22-Rv1 cells demonstrated a sig-
nificant reduction in DNA binding of the Sp1 transcrip-
tion factor to the ATM promoter, and quantitative
reverse transcription-PCR showed a 50% reduction of
ATM mRNA between 8 and 16 h of TPA treatment,
indicating that TPA inhibits ATM transcription. Fur-
thermore, treatment of LNCaP, CWR22-Rv1, PC-3, and
DU-145 human prostate cells with antisense-ATM oli-
gonucleotides, which markedly reduced cellular ATM
levels, significantly enhanced radiation-induced CS ac-
tivation and apoptosis, leading to apoptosis at doses as a
low as 1 gray. These data suggest that the CS pathway
initiates a generic mode of radiation-induced apoptosis
in human prostate cancer cells, regulated by a suppres-
sive function of ATM, and that ATM might represent a
potential target for pharmacologic inactivation with po-
tential clinical applications in human prostate cancer.
Prostate cancer is regarded as relatively resistant to the
lethal effects of radiation (3, 4). Consistent with this notion, the
androgen-responsive LNCaP human prostate cancer cells man-
ifest resistance to both radiation-induced apoptosis (5, 6) and
reproductive (postmitotic) cell death (7, 8). Our previous stud-
ies showed that the apoptotic resistance of LNCaP cells to
radiation can be reversed by pretreatment with the phorbol
ester 12-O-tetradecanoylphorbol 12-acetate (TPA)1 (1). TPA
commonly signals protection against apoptotic cell death (9),
such as induced by tumor necrosis factor  (10, 11), chemother-
apy (12), growth factor withdrawal (13), and radiation (14).
However, in a few cell types including Epstein-Barr virus-
infected Burkitt lymphoma cells (15), immature thymocytes
(16), salivary gland acinar cells (17), human MCF-7 breast
cancer cells (18), and LNCaP cells (19), TPA was reported to
induce and/or enhance the apoptotic response rather than sig-
nal antiapoptosis. The apoptotic response to TPA is mediated
via protein kinase C (PKC) activation, substituting for endog-
enous diacylglycerol (20). When PKC activity was compared in
TPA-sensitive (LNCaP) and -insensitive (PC-3, DU-145) pros-
tate cancer cell lines, it was found that PKC activation was
markedly enhanced and prolonged in LNCaP cells (21).
Garzotto et al. (19) defined a mechanism for the proapoptotic
effect of TPA, reporting that treatment of LNCaP cells with
TPA at maximally effective doses induces a weak apoptotic
response via activation of the regulatory enzyme ceramide syn-
thase (CS) and de novo synthesis of the sphingolipid ceramide.
Ceramide is an established second messenger in signaling
pathways of apoptosis induced by cytokines (i.e. Fas or tumor
necrosis factor), and environmental stresses (e.g. heat shock
(22), serum starvation (23), and radiation (14)). CS catalyzes
the condensation of the sphingoid base sphinganine and fatty
acyl-CoA to form dihydroceramide, which is rapidly oxidized to
form ceramide (24). Consistent with CS conferring an apoptotic
response in LNCaP cells, Garzotto et al. (19) showed that
TPA-mediated generation of ceramide and apoptosis were ab-
rogated by fumonisin B1 (FB1), a specific natural inhibitor of
CS activation. Subsequent studies by Garzotto et al. (1) showed
that TPA also converted the radiation resistance of LNCaP
cells, conferring radiosensitivity. The mechanism by which
TPA enables CS activation remains unknown. Studies by Liao
et al. showed that radiation-induced DNA double strand breaks
signaled in bovine aortic endothelial cells post-translational
activation of CS, whereas the ataxia telangiectasia mutated
(ATM) kinase, also activated by DNA double strand breaks,
down-regulated this response (2). These studies suggested that
the balance between CS activation and ATM-mediated CS re-
pression may determine the apoptotic outcome.
ATM is a nuclear 350-kDa protein kinase with a carboxyl-
terminal phosphatidylinositol 3-kinase-like kinase domain
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(25). It functions as a member of a coordinated system that
detects DNA breaks; arrests the cells temporarily at G1, S, or
G2 checkpoints; and activates DNA repair (26). ATMmutations
produce the genetic disorder ataxia telangiectasia (AT), char-
acterized by dysfunction of the immune, nervous, and endo-
crine systems (27, 28). At the cellular level, the AT phenotype
manifests chromosomal instability (29), increased frequency of
malignant transformation (30), defective G1, S, and G2/M cell
cycle checkpoints (31, 32), and hypersensitivity to ionizing ra-
diation (33). Transfection with full-length ATM cDNA (34) or
with cDNA fragments that contain its carboxyl-terminal phos-
phatidylinositol 3-kinase domain (35) restored normal radio-
sensitivity and radiation-induced cell cycle checkpoints in AT
cells, indicating that the AT radiation hypersensitivity is me-
diated via its protein kinase activity. Under resting conditions,
there is evidence that ATM is a functionally inactive dimer
(36). Radiation induces rapid intermolecular autophosphoryla-
tion of serine 1981 that leads to dimer dissociation and ATM
kinase activation (36). The downstream signaling pathways
are only partially known (37), and details of the ATM repres-
sive effect of CS activity are lacking.
The present studies show that TPA-mediated radiosensitiza-
tion of human prostate cell lines is mediated via suppression of
ATM activity. TPA induces a reduction in ATM protein levels
due to attenuation of the Sp1 transcription factor binding to the
ATM promoter. Reduction of ATM protein enables radiation to
increase CS activity, generating ceramide to induce apoptotic
cell death. Conclusive evidence for the role of ATM in this
response was obtained by the use of antisense ATM ODNs that
depleted human prostate cells of ATM. Antisense ATM-ODNs
conferred hypersensitivity to radiation-induced apoptosis in
LNCaP cells, enabling radiation-induced apoptosis at doses as
low as 1 Gy. Thus, the present studies define the mechanism of
TPA-mediated radiosensitization in human prostate cell lines,
providing further evidence that the balance between CS and
ATM activation regulates a generic form of radiation-induced
cell death in prostate cancer cells.
EXPERIMENTAL PROCEDURES
Materials—The human prostate cancer cell lines LNCaP, PC-3, and
DU-145 were obtained from ATCC. The androgen-sensitive human
prostate cancer cell line CWR22-Rv1 was kindly provided by Dr. Jacob-
berger from Case Western Reserve University (Cleveland, OH) (38). All
cell lines were incubated at 37 °C in a humidified 5% CO2 atmosphere.
Unless otherwise stated, all cell culture products were obtained through
Mediatech (800-Cellgro). The prostate cancer cell lines were cultured in
RPMI 1640 supplemented with 10% fetal calf serum (Gemini Bio-
products), 2 mM L-glutamine, 100 units/ml penicillin and 100 g/ml
streptomycin, and 10 mM HEPES (pH 7.2; Cellgro). For experiments,
cells were cultured in the same medium, except 0.2% human albumin
was substituted for fetal calf serum. TPA (Sigma) was diluted to a
concentration of 1 mg/ml in Me2SO and stored in 30-l aliquots at
20 °C in the dark until use. Polyclonal anti-Sp1 antibody (Sp1pEp2)
was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Quantification of Apoptosis—Morphologic changes in the nuclear
chromatin of cells undergoing apoptosis were detected by staining with
the DNA-binding fluorochrome bis-benzimide trihydrochloride (Ho-
echst-33258), as previously described (19). Cells were scored as apo-
ptotic when they displayed at least 3 apoptotic bodies/nucleus.
CS Assay—CS activity was assessed in microsomal membranes, as
described by Bose et al. (39). Briefly, cells were disrupted on ice by
sonication in lysis buffer containing 25 mM HEPES, pH 7.4, 5 mM
EGTA, 50 mM sodium fluoride, and protease inhibitor mixture (Roche
Applied Science). The microsomal fraction was purified by centrifuga-
tion at 100,000  g for 1 h, and the microsomal membrane pellet was
resuspended in lysis buffer. A total of 75 g of microsomal membrane
fraction was incubated with 1 ml of reaction buffer containing 2 mM
MgCl2, 20 mM HEPES (pH 7.4), 20 M defatted bovine serum albumin,
70 M unlabeled palmitoyl coenzyme A, 3.6 M (0.1 Ci) [1-14C]palmi-
toyl-coenzyme A, and escalating amounts of dihydrosphingosine (0, 1,
2.5, 5, and 10 M). This mixture was incubated at 37 °C for 1 h. The lipid
fraction was dried under N2 and resuspended in 50 l of a chloroform/
methanol (1:2, v/v) solution containing 1 mg/ml ceramide and diacyl-
glycerol. Lipids were resolved on a silica gel 60 thin layer chromatog-
raphy plate (Whatman) in a solvent consisting of chloroform, methanol,
3.5 N NH4OH (85:15:1, v/v/v). The ceramide band was localized by iodine
vapor staining based on comigration with commercially available cer-
amide (Sigma Type III) and quantified using liquid scintillation count-
ing. Under the conditions used, the substrate was not rate-limiting, and
the reaction was linear for the time and enzyme concentration. Deter-
mination of Km and Vmax was performed using Eadie-Hofstee analysis
as described by Bose et al. (39).
Quantitation of Ceramide Levels—Ceramide was quantified using
the diacylglycerol kinase assay as previously described (1). Briefly,
LNCaP cells were detached from the monolayer by gentle pipetting. The
cells were pelleted by centrifugation (500  g for 5 min), washed with
ice-cold phosphate-buffered saline, and extracted with 1 ml of ice-cold
methanol. Further extraction was performed with 600 l of buffered
saline solution (135 mM NaCl, 1.5 mM CaCl2, 0.5 mM MgCl2, 5.6 mM
glucose, and 10 mM HEPES (pH 7.2)) with 10 mM EDTA. Lipids in the
organic phase extract were dried under N2 and subjected to mild alka-
line hydrolysis (0.1 N methanolic KOH for 1 h at 37 °C) to remove
glycerophospholipids. Samples were re-extracted, and the organic
phase was dried under N2. Ceramide was quantified by the DG kinase
assay as described (1).
Analysis of ATM Protein Expression—Cells were lysed in radioim-
mune precipitation buffer and centrifuged at 18,000  g for 15 min to
remove membranes and nuclear DNA. The concentration of protein in
the samples was determined using the BCA technique, purchased from
Pierce, and performed as per the manufacturer’s instructions. Samples
were then boiled in 4 denaturing Laemmli sample buffer and stored at
80 °C. ATM was resolved using a 5% low cross-linked SDS gel. Mono-
clonal anti-ATM antibody MAT3 was kindly given by Prof. Y Shiloh
(Tel-Aviv University, Tel-Aviv, Israel), whereas the anti-mouse horse-
radish peroxidase secondary antibody was purchased from Santa Cruz
Biotechnology and used at a 1:1000 dilution. The bands were revealed
using Western Lightning chemiluminescence reagent (PerkinElmer
Life Sciences) as per the manufacturer’s instructions. For the loading
controls, the membranes were first stripped using 100 mM Tris-HCl, pH
6.8, 100 mM -mercaptoethanol, and 2% SDS for 1 h at 50 °C, and then
the membranes were washed three times in TBS with 0.1% Tween 20.
The membrane was reprobed using an anti-DNA-PKcs monoclonal an-
tibody (Neomarkers) at a 1:200 dilution, and the bands were revealed
using the same protocol as used for anti-ATM. For densitometry, the
bands corresponding to ATM were scanned and analyzed using ImageJ
version 1.29 image analysis software.
mRNA Analysis—Levels of mRNA were analyzed by quantitative
PCR as described (40). Briefly, during the PCR process, known amounts
of 402-bp DNA fragments corresponding to a mutation of ATM lacking
exon 38 were used in 2-fold dilutions as a competitor for the amplifica-
tion of the same region in normal ATM, which gave a 544-bp fragment.
A DNA fragment (402 bp) corresponding to an ATMmutation (G5319A)
lacking exon 38 was employed as a competitor of ATM cDNA amplifi-
cation (nucleotides 5122–5665, 544 bp in size) in a series of 2-fold
dilutions from LNCaP cells. When the amplified bands showed the
same intensity, this provided the concentration of ATM mRNA.
Electrophoretic Mobility Shift Assay—Binding of Sp1 to its consensus
sequence was determined by a modification of a method described
previously (40). Briefly, 6  106 cells were washed in ice-cold phos-
phate-buffered saline before resuspension in 10 mM HEPES, pH 7.9,
buffer containing 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM
dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride. After a 15-
min incubation on ice, 25 l of 10% Nonidet P-40 was added, then the
sample was vortexed for 10 s before centrifugation at 18,000  g for 1
min. The pellet was resuspended in 40 l of 20 mM HEPES, pH 7.9,
containing 400 mM KCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1 mM
dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride and rotated
for 30 min at 4 °C to elute the nuclear proteins. After further centrifu-
gation at 18,000  g for 5 min, the supernatant was flash-frozen in
liquid nitrogen in 15-l aliquots and stored at 70 °C. Approximately
35 fmol of 32P-labeled (using T4 polynucleotide kinase) double-stranded
Sp1 consensus sequence (5-ATTCGATCGGGGCGGGGCGAGC-3) was
added to 10 g of nuclear extract in the presence of 1 g of herring
sperm DNA, 10 g of bovine serum albumin, and binding buffer con-
sisting of 10 mM HEPES pH 7.9, 50 mM KCl, 0.5 mM EDTA, 10%
glycerol, 0.1% Nonidet P-40, 5 mM dithiothreitol, and 0.2 mM phenyl-
methylsulfonyl fluoride. Binding was at room temperature for 25 min,
and then the bands were resolved using a native 5% polyacrylamide gel.
Transfection Studies—FLAG-tagged wild type and kinase-dead
ATM, which has a deletion of 200 bp in the 3 region in the pcDNA3
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vector, were kindly provided by Dr. Michael Kastan (St. Jude Children’s
Research Hospital, Memphis, TN) and have been previously described
(41). The plasmids were transfected into the cells using Lipofectamine
PLUS (Invitrogen) as per the manufacturer’s instructions. 24 h follow-
ing transfection, cells were selected in normal medium containing 200
g/ml of G418 (Invitrogen), and G418-resistant colonies were expanded.
Cells expressing the highest level of transfected ATM (WT8.4) by West-
ern blot were selected for experiments. Small interfering RNA (siRNA)
targeted against Sp1 and the control sequence were derived from se-
quences previously published (42). A 100 nM concentration of either
siRNA against Sp1 or control was transfected into LNCaP using Oligo-
fectamine (Invitrogen) as per the manufacturer’s instructions. The ef-
ficacy of the siRNA was determined by Western blot against Sp1 pro-
tein, which showed significant reduction in Sp1 protein levels 24 h after
treatment.
Antisense Inactivation of ATM—For antisense experiments, morpho-
lino oligonucleotides (ODNs) purchased from Gene Tools LLC (Philo-
math, OR) were used. Morpholino ODNs have the advantage of being
more stable and more resistant to endonucleases and have a better
sequence specificity than phosphorothioate ODNs (43, 44). For target-
ing of ATM mRNA, the first 25 bases of the mRNA sequence (ACTA-
GACTCATGGTTCACAATTTCA) were used as recommended by the
manufacturer (Gene Tools LLC). Morpholino ODNs were delivered to
the cell using the “Special Delivery” system (Gene Tools LLC), which is
a method for coupling the nonionic morpholino to complementary DNA
bound electrostatically to a partially ionized, weakly basic ethoxylated
polyethyleneimine. A total of 3 mol of morpholino ODN was used, and
after 3 h of treatment with the morpholino/ethoxylated polyethylenei-
mine mixture, the supernatant was removed and replaced with normal
medium. The cells were subsequently left in culture for either 4 days for
LNCaP cells or 3 days for CWR22-Rv1, PC-3, and DU-145 cells before
use, which represented the time of maximal reduction in ATM protein
level when analyzed by Western blot. Studies using fluorescein isothio-
cyanate-conjugated ODNs showed the efficiency of transfection to be at
least 65%.
Cell Cycle Studies—To determine the cell cycle distribution of the
preconfluent LNCaP cultures used in the present studies, a modifica-
tion of the protocol published by Pozarowski and Darzynkiewicz (45)
was used. Cells were incubated in 0.2% human albumin-containing
medium 16 h before irradiation, at which time TPA was added at 10
ng/ml. Cells were exposed to 20 Gy and collected every 12 h for 48 h. At
the different time points, cell were trypsinized and fixed in ice-cold 70%
ethanol and then stored at20 °C. 1 h before fluorescein isothiocyanate
analysis, the cells were centrifuged, and the ethanol solution was re-
placed with a 3.8 mM sodium citrate (Sigma) solution containing 50
g/ml propidium iodide (Sigma) and 100 units/ml RNase. The DNA
content of the nuclei was measured using FACScalibur, with 10,000
gated events counted, and data were analyzed using Flowjo version
6.1.1.
To determine the duration of cell traversal through the different cell
cycle phases, cells were blocked at the G1/S border using aphidicolin (50
g/ml) and washed out 24 h later. The cells were left to cycle for 2 h
before being pulse-labeled with bromodeoxyuridine (10 M) for 45 min
as per the manufacturer’s instructions (BD Pharmingen Flow Kit, San
Diego, CA). Cells were irradiated, and samples were taken every 4 h
over a period of 28 h and then fixed in 70% cold ethanol. LNCaP cells
were then incubated with anti-bromodeoxyuridine fluorescein isothio-
cyanate antibody, and total DNA was stained using 7-amino-actinomy-
cin D, as per the manufacturer’s instructions. Fluorescein isothiocya-
nate fluorescence was examined along with total DNA fluorescence
using flow cytometry (FACScalibur). 10,000 gated events were counted,
and the data were analyzed with Flowjo version 6.1.1.
Colony-forming Assay—LNCaP cells were either untreated or
treated with sense or antisense ATM ODNs as described above. LNCaP
cells were then irradiated with 0, 1, 2, and 3 Gy, trypsinized, and
replated in triplicate at various cell concentrations for colony formation.
Colonies were cultured for 2 weeks at 37 °C in a humidified 5% CO2
atmosphere in complete medium to allow for at least six cell divisions.
The surviving colonies were fixed and stained with 1% crystal violet in
0.2 M citric acid. Colonies with at least 50 cells were scored, and the
results were analyzed by the CellFit version 2.5 program (46).
RESULTS
To exclude the possibility that the effect of TPA represents a
LNCaP cell-specific phenomenon, we carried out experiments
with another androgen-responsive prostate cancer cell line,
CWR22-Rv1. TPA induced a time- and dose-dependent apo-
ptotic response in these cells (Fig. 1A), although induction of
apoptosis was slower than that reported in LNCaP cells (1). At
10 ng/ml, apoptosis became detectable by 32 h and peaked at
35–40% by 66 h (p  0.005). As little as 300 pg/ml TPA was
effective, and a maximal effect was achieved with 10–50 ng/ml
(data not shown). Pretreatment with a 40 M concentration of
the CS inhibitor FB1 markedly attenuated apoptosis to 12 
0.55% at 72 h from 30.1  1.15% observed with 10 ng/ml TPA
alone (Fig. 1B). These studies indicated that, similar to LNCaP,
CWR22-Rv1 cells respond to phorbol ester stimulation with
CS-mediated apoptosis. A kinetic analysis of CS activity dis-
closed maximal activation from 26 to 32 h post-TPA treatment
(Fig. 1C), which corresponded to the time when ceramide levels
were rising significantly (Fig. 1D). Eadee-Hofstee transforma-
tion of the data revealed that the maximal reaction velocity
increased from a basal level of 19.57 pmol/min/mg to 34.79
pmol/min/mg after TPA (p  0.01, stratified rank sum) without
a significant change in the Km. Consistent with this pattern, a
full-time analysis of ceramide levels in CWR22-Rv1 cells stim-
ulated by 10 ng/ml TPA (Fig. 1D) showed that ceramide levels
increased by 32 h from a base line of 103  17 pmol/106 cells to
225  45 pmol/106 cells (p  0.01, Wilcoxon rank sum) and
remained elevated until 66 h post-treatment (Fig. 1D). Fur-
thermore, similar to the effects of TPA plus radiation in LNCaP
cells (1), subtoxic levels of TPA (300 pg/ml), which were insuf-
ficient for induction of significant apoptosis in CWR22-Rv1
cells (7.5  1.2% apoptosis, p  0.5), conferred radiation sen-
sitivity to apoptotic response after 20 Gy (Fig. 1E, p  0.01,
stratified rank sum). Taken together, these data indicate that
TPA induction of CS-mediated apoptosis is not a LNCaP-spe-
cific phenomenon, since it is also activated in another human
prostate cancer cell line.
Because ATM was reported to suppress radiation-induced
CS activation in some cell types (2), experiments were carried
out to assess the possibility that the proapoptotic effect of TPA
is mediated via the reduction of ATM function. LNCaP cells
were treated with TPA (10 ng/ml) for 16 h, conditions optimal
for TPA-induced CS activation in these cells (1), and ATM
levels were examined by Western blot analysis. Fig. 2A shows
that there was a 65% reduction in ATM protein levels by
pretreatment with 10 ng/ml TPA. Radiation alone (20 Gy) had
no significant effect on ATM; nor did radiation have any addi-
tional effect on the ATM levels when combined with TPA
treatment.
Since it was previously reported that inhibition of Sp1 bind-
ing can lead to a decrease in ATM mRNA and protein levels in
response to epidermal growth factor in C3ABR lymphoblastoid
cells (47), Sp1 binding to its consensus oligonucleotide was
measured in TPA-treated LNCaP cells. Gel shift analysis
showed a significant reduction in the amount of Sp1 binding to
its consensus sequence in extracts from LNCaP cells as early as
4 h post-TPA treatment, peaking at 16 h (Fig. 2B). Anti-Sp1
antibodies, which produced a supershift of the retarded band
(Fig. 2B, first lane), confirmed the specificity of this interaction.
Consistent with TPA-mediated transcriptional regulation of
ATM expression in LNCaP, reduced expression of ATM protein
was also detected in CWR22-Rv1 cells after a 16-h incubation
with 10 ng/ml TPA (Fig. 2C). ATM protein levels were reduced
to 38% of the control after 16 h and remained low for as long as
48 h (Fig. 2C and data not shown). Reduced DNA binding of
Sp1 was also detected in CWR22-Rv1 cells as early as 8 h after
incubation with TPA and remained low for at least 16 h (Fig.
2D). Exposure to 20 Gy had no significant effect on ATM
protein levels (Fig. 2C) or on Sp1 binding (not shown). These
data are consistent with TPA-induced down-regulation at the
transcriptional level as causative in the reduction in ATM
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FIG. 1. TPA-mediated apoptosis in prostate cancer cell line CWR22-Rv1. A, time course for TPA-mediated apoptosis induction. Apoptosis
was measured by bis-benzimide staining at the indicated times. B, FB1 inhibits TPA-mediated apoptosis. Cells were pretreated with 40 M FB1
for 3 h before 10 ng/ml TPA was added. Apoptotic nuclei were counted after 48- and 72-h incubation by bis-benzimide staining. C, ceramide
synthase in TPA-treated CWR22-Rv1 cells. CS activity was measured after incubating the cells with 10 ng/ml TPA for the indicated time. D,
ceramide levels following incubation with 10 ng/ml TPA. Samples of TPA-treated cells were taken at the time points shown. Ceramide levels were
measured by the diacylglycerol kinase assay, and the bars represent S.D. values. E, effect of radiation on TPA-mediated apoptosis. Cells were
incubated with 300 pg/ml TPA for 16 h before irradiation at 20 Gy. Apoptotic nuclei were counted using bis-benzimide staining 72 h after
irradiation. This dose of TPA that alone was insufficient to induce significant apoptosis conferred radiation sensitivity (p  0.01; stratified rank
sum) in CWR22-Rv1 cells. The bars represent S.D. values. All studies were repeated at least twice.
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FIG. 2. TPA down-regulates ATM protein levels in LNCaP and CWR22-Rv1 cells. A, Western blot analysis of ATM expression in LNCaP.
LNCaP cells were treated either with 20 Gy, with 10 ng/ml TPA, or with TPA for 16 h followed by 20 Gy. B, gel shift assay of Sp1 binding following
TPA incubation in LNCaP. LNCaP cells were incubated with 10 ng/ml TPA for the indicated times and compared with nonstimulated samples (NS).
The first lane shows supershifted Sp1 caused by incubating the sample with anti-Sp1 antibody. C, Western blot analysis of ATM expression in
CWR22-Rv1. CWR22-Rv1 cells were treated either with 20 Gy, with 10 ng/ml TPA, or with TPA for 16 h followed by 20 Gy. The intensity of the
band compared with the nonstimulated control is also shown. Equal loading was ensured by reblotting filters with anti-DNA-PKcs antibody. D,
gel shift assay of Sp1 binding following TPA incubation in CWR22-Rv1. CWR22-Rv1 cells were incubated with 10 ng/ml TPA for the indicated times
and compared with NS samples. The first lane shows supershifted Sp1 caused by incubating the sample with anti-Sp1 antibody. E, competitive
reverse transcriptase-PCR analysis of ATM mRNA. Samples from TPA-treated LNCaP cells were taken after 8, 12, and 16 h of incubation. The
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protein levels and radiation hypersensitivity in LNCaP and
CWR22-Rv1 cells.
To further explore this notion, competitive reverse tran-
scriptase-PCR was employed. A DNA fragment (402 bp) corre-
sponding to an ATM mutation (G5319), which lacks exon 38,
was used as a competitor for ATM cDNA amplification (nucle-
otides 5122–5665, 544 bp in size) in a series of 2-fold dilutions
of extracts from LNCaP cells. After 8 h of treatment with TPA,
an equivalence point was reached at 0.25 amol/l of the com-
petitor. Compared with the equivalence point of 0.5 amol/l for
untreated cells, the effect of TPA represents a 2-fold reduction
in ATM mRNA in response to TPA (Fig. 2E). The same equiv-
alence point was reached after 12 and 16 h of TPA treatment,
representing a significant sustained 2-fold reduction in ATM
mRNA (Fig. 2E).
To more specifically assess whether the loss of Sp1 binding
yielded a reduction in ATM mRNA abundance, the effect of
siRNA against Sp1 was tested. No change in ATM protein
levels was detected after Sp1 protein down-regulation (Fig. 2F),
consistent with previously published studies showing that the
regulation of ATM gene is controlled by several different tran-
scription factors (48). However, when LNCaP were treated
with suboptimal doses of TPA (0.6 ng/ml) in conjunction with
siRNA against Sp1, ATM protein levels were markedly reduced
(47% of control; Fig. 2F, upper right panel), whereas the same
concentration of TPA had no effect on ATM levels in cells
treated with unrelated siRNA (Fig. 2F, middle right panel).
These data suggest that Sp1 inhibition is required for the TPA
effect on ATM transcription, although an additional effect of
TPA, possibly via another transcription factor of the ATM
promoter, is concomitantly required.
To confirm that reduction in ATM is required for TPA-in-
duced apoptosis, full-length ATM was stably transfected into
LNCaP cells under control of a cytomegalovirus promoter to
compensate for the reduction of ATM in TPA-treated cells.
LNCaP cells transfected with wild type ATM showed a signif-
icant attenuation of apoptosis at 48 and 72 h post-TPA (from
54.5  1.4% in vector-transfected control cells at 72 h incuba-
tion with TPA to 8.7  1.1%, (Fig. 3)). The ATM-transfected
cells also showed significant reduction of TPA-mediated radio-
sensitization, from over 70% apoptosis in vector-transfected
control cells after 72 h of 10 ng/ml TPA plus 20 Gy radiation to
less than 30% in ATM-transfected cells. The inset shows ATM
protein levels in WT8.4 and the control cell line after 16 h of
TPA-treatment, indicating that whereas control cells had sig-
nificantly decreased ATM levels, the ATM-transfected cells
expressed high ATM protein levels. These results support the
notion that the level of cellular ATM determines the apoptotic
response to TPA and TPA plus radiation in human androgen-
responsive prostate cells.
To provide genetic evidence for the role of ATM in the apo-
ptotic sensitivity of prostate cancer cells, LNCaP and CWR22-
Rv1 cells were treated with 3 mol of ATM sense (S-ATM) or
antisense (AS-ATM) ODNs. A reduction in ATM protein levels
was detected as early as 48 h (not shown) with a nadir of 25 and
40% of control at 96 and 72 h in AS-ATM-ODN-treated LNCaP
and CWR22-Rv1 cells, respectively (Fig. 4, A and B). However,
ATM loss of function was not sufficient by itself to elicit an
apoptotic response, and an additional stimulus, such as radia-
tion exposure, appeared to be required. Fig. 4, C and D, shows
that when ATM was effectively suppressed in both LNCaP and
CWR22-Rv1 cells by AS-ATM-ODN, the level of apoptosis was
not significantly different from S-ATM-ODN-treated or ODN-
untreated cells. However, when exposed to 20 Gy, over 30% of
the cells underwent apoptosis, significantly higher than in
S-ATM-ODN-treated or ODN-untreated cells. The apoptotic
response in AS-ATM-ODN-treated cells was inhibited by FB1
(Fig. 4, C and D), confirming that ATM down-regulation en-
ables CS-mediated apoptosis after radiation exposure.
To establish the level of radiosensitization conferred by ATM
loss of function, LNCaP cells were either untreated or treated
with S-ATM or AS-ATM ODNs before exposure to escalating
doses of radiation. Apoptosis was quantified 24 and 48 h after
irradiation. Fig. 4E shows that AS-ATM-ODN sensitized LN-
CaP cells to doses as low as 1 Gy at 48 h postirradiation (18.7
0.6% apoptosis, compared with 7.4  0.54% for S-ATM-ODN
and only 3.4  0.2% for ODN-untreated cells, p  0.0003), and
a maximal level of apoptosis was achieved at 20 Gy (32 
0.73%, compared with 7.4  0.59% in S-ATM-ODN-treated
cells and 3.5  0.46% in ODN-untreated cells; p  0.0003). At
the clinically relevant dose of 2 Gy, the level of apoptosis
attained with AS-ATM-ODN (23.1  0.41%) was already at
72% of the maximum effect observed with 20 Gy. The radio-
sensitizing effect of AS-ATM-ODN at 2 Gy was observed as
early as at 24 h postirradiation (16.1  0.39%, compared with
6.9  0.4% for S-ATM-ODN and only 2.4  0.3% for ODN-
untreated cells; p  0.0016; data not shown). We also assessed
the effects of AS-ATM-ODN on LNCaP cell survival after irra-
diation using the colony-forming assay. Fig. 4F shows that
S-ATM-ODN has no significant effect on cell survival when
compared with ODN-untreated cells. However, pretreatment
with AS-ATM-ODN resulted in significant radiosensitization,
with a decrease of the Dq (ODN-untreated 1.135 Gy, S-ATM-
ODN  1.021 Gy and 0.00 for AS-ATM-ODN) and a shift of the
arrows show the equivalence point denoting where the levels of PCR product are the same. F, Western blot analysis of the effect of Sp1 siRNA on
TPA-induced ATM down-regulation. LNCaP cells transfected 24 h previously with a 100 nM concentration of control or Sp1 siRNA were
subsequently treated with different concentrations of TPA for 16 h before ATM levels were analyzed. Densitometry of the ATM Western blots is
also shown, with protein levels compared with the non-TPA-treated cells. Loading controls are included. The boxed area shows the effect of either
nontreated (NT), control unrelated siRNA-treated (Ctl), and Sp1 siRNA-treated (Sp-1) LNCaP 24 h after transfection on Sp1 protein levels.
Densitometry shows the level of inhibition as compared with the control, and loading controls (DNA-PKcs) are also shown. All of the studies were
repeated at least twice.
FIG. 3. Reduction in ATM protein is required for TPA-medi-
ated apoptosis. Apoptotic analysis of wild type ATM-transfected LN-
CaP (WT8.4) compared with empty vector-transfected LNCaP (Control).
TPA-treated cells were first preincubated for 16 h before irradiation at
20 Gy and then incubated for 48 or 72 h before apoptosis was quantified
by bis-benzimide staining. The bars represent S.D. values. The inset
shows ATM protein levels in WT8.4 and control cells after 16 h of TPA
treatment, along with DNA-PKcs as a loading control. All studies were
repeated three times.
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survival curve to the low dose range, without a significant
change in the D0 (ODN-untreated  0.802 Gy, S-ATM-ODN 
0.837 Gy, and 0.830 Gy for AS-ATM-ODN). At the clinically
relevant dose range, the SF2 (the survival fraction at 2 Gy) was
0.24 for ODN-untreated and S-ATM-ODN-treated and 0.07
(p  0.05) for AS-ATM-ODN-treated cells (Fig. 4F).
To confirm that the FB1-inhibitable radiation-induced apo-
ptosis conferred through AS-ATM ODN is through CS, CS
activity was measured. Since CS activation in TPA-treated
LNCaP occurs faster or at a higher level than in CWR22-Rv1
(1, 19) (Fig. 1, C and D), LNCaP cells were harvested after 3 h
of irradiation, whereas CWR22-Rv1 cells were harvested 16 h
after irradiation. Fig. 5A shows that in LNCaP cells exposed to
20 Gy, CS activity increased significantly only in cells treated
with AS-ATM-ODN (p  0.01, stratified rank sum). Eadee-
Hofstee analysis of the kinetic data revealed that the Vmax
increased from a base line of 119.9 pmol/min/mg protein to
257.3 pmol/min/mg protein, without a significant change in the
FIG. 4. ATM antisense ODNs mimic the radiosensitizing effects of TPA. Analysis of ATM protein levels in LNCaP (A) and CWR22-Rv1
(B) cells following treatment with 3 mol of sense (S) or antisense (AS) or equal amounts of antisense and sense (AS  S) morpholino ODNs. A
nontransfected control is also shown (NS). Band intensity is shown as a percentage of the nontransfected control band. Below are the protein
loading controls. Shown is quantification of apoptosis following radiation treatment of transfected LNCaP cells (C) or CWR22-Rv1 cells (D). 40 M
FB1 was administered where indicated 3 h before 20 Gy. Cells were harvested after 24 h for C and 48 h for D. Apoptosis was quantified by counting
bis-benzimide-stained nuclei. The bars represent S.D. values. E, cells were either untransfected (Control) or transfected with either sense (S) or
antisense (AS) morpholino ATM 96 h before irradiation. The cells underwent medium change to 0.2% human albumin RPMI and were irradiated
at the indicated doses. Apoptosis was measured after a 48-h incubation at 37 °C using the bis-benzimide method. Data shown are mean S.D. from
two independent experiments. F, LNCaP cells were either nontransfected or transfected with either sense or antisense ATM-ODNs, and after 96 h,
they were irradiated at various doses. The cells were subsequently replated at known concentrations before culture for 2 weeks. The curves were
fit to the data using the single-hit, multiple target (SHMT) model of radiation sensitivity. Each data point represents the mean average of six
separate determinations, with S.D. values shown.
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Km. Fig. 5B demonstrates that, similarly, pretreatment with
AS-ATM-ODN significantly increased CS activity in CWR22-
Rv1 cells at 16 h after 20 Gy (Fig. 5B), increasing the Vmax from
0.66 pmol/min/mg protein in nontransfected or in S-ATM-ODN-
transfected cells to 16.62 pmol/min/mg protein in AS-ATM-
ODN-transfected cells (p  0.01, stratified rank sum). For both
cell lines, FB1 inhibited the AS-ATM-ODN-mediated CS acti-
vation after irradiation (Fig. 5).
Subsequent to CS activation, there was also a rise in cellular
ceramide. Because of the difference in the kinetics of CS acti-
vation, LNCaP cells were collected for measurement of ceram-
ide levels at 12 h after irradiation, whereas CWR22-Rv1 cells
were collected at 24 h after irradiation. Fig. 6, A and B, shows
that both cell types treated with AS-ATM-ODN exhibited a
significant increase in ceramide levels when exposed to 20 Gy
as compared with base-line levels observed in ODN-untreated
cells and in S-ATM-ODN-treated cells (p 0.01, Wilcoxon rank
sum), which were inhibited by FB1. Fig. 6C shows the gener-
ation of ceramide after exposure to escalating doses of radiation
in AS-ATM-ODN-treated cells. Exposure to as low a dose as 1
Gy resulted in a rise in ceramide (499.5 pmol/106 cells, com-
pared with 448 pmol/106 cells for S-ATM-ODN-treated or ODN-
untreated cells), reaching a maximum plateau at 20 Gy. Taken
together, these studies provide conclusive evidence that reduc-
tion of ATM is required to confer CS-mediated apoptotic radio-
sensitization of LNCaP and CWR22-Rv1 cells. Reduction of
ATM alone is not sufficient, and a second stimulus, such as
provided by as low a dose of radiation as 1 Gy is required to
activate CS-mediated synthesis of ceramide and apoptosis.
Whereas previous publications have indicated that ATM in-
hibition affects progression through the G2/M checkpoint (32,
49) and that progression through this cell cycle checkpoint
affects radiation sensitivity (50–52), we tested the effects of
TPA or AS-ATM-ODN on G2/M in our LNCaP cells. The distri-
bution of control LNCaP cells by cell cycle phase immediately
prior to radiation (69.5% in G1, 4.7% in S phase, and 21.8% in
G2/M) was not significantly different from published values for
this cell type (53). Furthermore, as published in the literature
(53), exposure to 10 Gy did not result in a significant increase
of LNCaP cells in G2/M, (20.7  1.6% at 24 h and 24.5  1.8%
at 48 h) regardless of pretreatment with TPA (10 ng/ml), S-
ATM-ODN, or AS-ATM-ODN. There were also no significant
differences in the duration of cells traversing through G2/M,
regardless of TPA, S-ATM-ODN, or AS-ATM-ODN treatment
with or without radiation (7.8  0.45 h) as measured by flow
cytometry of LNCaP cells using anti-bromodeoxyuridine fluo-
rescein isothiocyanate staining of DNA. These data indicate
that the radiosensitization conferred by reduction of cellular
ATM in LNCaP cells did not result from alterations of radia-
tion-induced G2/M arrest.
We also tested whether decreasing ATM levels elicits an
apoptotic response to radiation in TPA-resistant human pros-
tate cancer cells PC-3 and DU-145. Cells were either untreated
or transfected with sense or antisense ATM ODNs. ATM pro-
tein down-regulation was confirmed by Western blotting and
showed to be at 38% of the nontransfected level for PC-3 and at
32% for DU-145 (data not shown). Ceramide levels in PC-3 and
DU-145 cells measured 24 h after 20-Gy irradiation (Table I)
exhibited increases that mirrored those observed in LNCaP
and CWR22-Rv1. Whereas nontransfected and sense-trans-
fected cells showed no significant increase in ceramide after
20-Gy irradiation, AS-ATM ODN transfected cells showed sig-
nificantly higher levels of ceramide. FB1 was able to inhibit the
ceramide increase by 75.4% for PC-3 and 100% for DU-145,
indicating that the ceramide elevations conferred by AS-ATM-
ODNs reflected CS activation in all prostate cancer cell lines
examined in this study. Apoptosis was quantified 48 h after
irradiation using the same protocol as for LNCaP and CWR22-
Rv1 cells (Table I). Whereas the nontransfected and sense ATM
ODN-transfected cells did not undergo significant apoptosis
after 20 Gy (3.5  0.1% for PC-3 and 6.3  2.9% for DU-145),
AS-ATM-ODN-treated cells were radiosensitive, albeit with
different efficiencies (14.8  1.0% PC-3, 27.5  3.3% for DU-
145). The radiation-induced apoptosis in AS-ATM-ODN-trans-
fected cells was significantly inhibited with FB1 (76.1% inhibi-
tion for PC-3 cells, 57.5% inhibition for DU-145), strongly
indicating that the mechanism of apoptotic induction in all of
the cell lines tested is CS-mediated.
DISCUSSION
The present studies show that TPA decreases ATM protein
levels in androgen-sensitive human prostate cancer cells, an
event crucial for TPA-induced apoptosis and TPA-mediated
radiosensitization of these cells. The alteration in ATM protein
levels appeared to be due to inhibition of ATM transcription via
decreased binding of Sp1 to the ATM promoter, although the
Sp1 siRNA experiments indicated that decreased Sp1 binding
was required but not sufficient for down-regulation of ATM
transcription. The additional TPA-mediated effector in down-
regulating ATM transcription remains unknown; nor is there
information on the precise mechanism by which TPA effects
Sp1 function. Sp1 can be phosphorylated (54, 55), which has
been implicated in altering its interaction with Sp1 cognate
DNA binding sites and transcriptional activation and can also
be O-glycosylated, thus affecting the protein stability and its
FIG. 5. Reduction in ATM protein levels enables radiation ac-
tivation of CS. LNCaP cells were transfected 96 h before irradiation,
and CWR22-Rv1 cells were transfected 72 h before irradiation. Cells
were preincubated with 40 M FB1 where indicated for 3 h prior to
irradiation. CS activation was quantified in LNCaP cells 3 h postirra-
diation (A) and in CWR22-Rv1 cells 16 h postirradiation (B). Shown are
nontransfected cells (NT), sense-treated cells (S), and antisense-treated
cells (AS). The graphs are representative of one of at least three sepa-
rate experiments.
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interaction with other factors (56). Furthermore, specific inter-
action of ATM with Sp1 suggests that Sp1 may be a substrate
for ATM kinase (48). Substantive additional investigation into
the biochemical mechanism of ATM regulation appears
warranted.
TPA-mediated activation of PKC may also be involved in
this process. Our recent studies using LNCaP cells showed
that, similar to the TPA effect, PKC activation by its specific
activator, the branched diacylglycerol-lactone (previously
named HK-654), results in reduction of cellular ATM levels and
apoptosis (57). The catalytic domain of activated PKC is re-
quired for this event, since LNCaP cells transfected with a
kinase-dead dominant-negative mutant of PKC showed no
decrease in ATM protein. Treatment of LNCaP cells with
branched diacylglycerol-lactone also resulted in ceramide gen-
eration and apoptosis, both inhibitable by FB1, consistent with
CS activation occurring secondary to PKC-mediated ATM
reduction. Whether Sp1 is a direct target for activated PKC
remains unknown. Our recent unpublished experiments2
showed that TPA also activates PKC in LNCaP cells, which
translocates to the mitochondria and is inhibitable by FB1.
Recent evidence also indicates that PKC, similar to other
atypical and novel PKC isoforms, may be activated by ceramide
via the C1b domain (58). Relevant to this observation are
studies indicating that in addition to the endoplasmic reticu-
lum, CS-mediated de novo synthesis of ceramide also localizes
to the mitochondria (59, 60) and that ceramide is involved, or
even likely to be required, for mitochondrial apoptosis in some
cells (61). Hence, activated PKC may function downstream of
CS activation in the TPA-mediated apoptotic pathway, al-
though its involvement in down-regulation of ATM transcrip-
tion as well cannot be excluded.
The enabling of CS-mediated apoptosis in both androgen-
sensitive and -insensitive prostate cancer cells via reduction of
ATM indicates that the interaction between ATM kinase and
CS may represent a generic mode of regulation of radiation-
induced death in these cells. Whereas ATM kinase normally
represses CS activity, a reduction in ATM protein by TPA or
AS-ATM-ODN treatment attenuates CS repression, enabling
ceramide synthesis and a proapoptotic state. However, the
experiments with AS-ATM-ODN indicated that ATM reduction
by itself is not sufficient to induce CS activation and that a
second signal, such as that provided by radiation, is required.
Consistent with this observation, TPA mimicked radiation in
inducing apoptosis in AS-ATM-ODN-treated LNCaP cells (not
shown). ATM inactivation by AS-ATM-ODN conferred extreme
radiation hypersensitivity, since the level of apoptosis attained
in AS-ATM-ODN-treated LNCaP exposed to 2 Gy was already
at 72% of the maximum effect observed with 20 Gy (32 
0.73%), both significantly higher than the 3.4  0.2% observed
after 20-Gy exposure of ODN-untreated cells (Fig. 4E). These
data suggest that efficient depletion of ATM may represent a
highly attractive target for radiosensitization associated with
DNA damage via CS activation.
2 J.-P. Truman, N. Gueven, M. Lavin, S. Leibel, R. Kolesnick, Z. Fuks,
and A. Haimovitz-Friedman, unpublished results.
Cells were incubated with 40 M FB1 where indicated for 3 h followed
by 20 Gy. Ceramide analysis was performed as in Fig. 1D. A, LNCaP
cells were examined 12 h postirradiation. B, CWR22-Rv1 were exam-
ined 24 h postirradiation. Data shown are mean  S.D. from two
independent experiments. C, LNCaP cells were either nontreated (NT)
or treated with either sense (S) or antisense (AS) ATM ODNs before
being exposed to increasing doses of radiation. Ceramide levels were
measured 12 h postirradiation. Data shown are mean S.D. from three
independent experiments.
FIG. 6. AS-ATM-ODN-treated cells generate ceramide in re-
sponse to 20-Gy radiation. LNCaP cells were transfected 96 h before
irradiation, and CWR22-Rv1 were transfected 72 h before irradiation.
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The mechanism by which ATM kinase regulates CS remains
unknown. Whereas ATM inhibition has been shown to affect
progression through the G2/M checkpoint in some cell types
(32, 49), our studies indicate that deregulation G2/M is not the
mechanism of prostate cancer cell radiosensitization. Mamma-
lian CS genes represent homologs of the yeast lag1 and lac1
genes (62) that either harbor CS catalytic activity or play some
other essential role in the CS reaction. The first human hom-
olog of lag1 identified is uog1 (63, 64), also known as LASS1.
There are six human homologs designated HLASS1 to -6. Rie-
beling et al. (63) have recently characterized mouse homologs of
LASS4 and LASS5 by overexpressing these genes in human
embryonic kidney 293T cells. They showed that LASS4-over-
expressing cells are preferentially enriched in C18- and C20-
ceramide, whereas the synthesis of C16-ceramide is increased
in LASS5-overexpressing cells. It should be emphasized that
pure enzyme has not yet been made, and hence identification of
these genes as legitimate synthases has not yet been con-
firmed. Nevertheless, screening of the amino acid sequences of
the six putative CS genes showed the SQ or TQ motif required
for direct interaction with ATM (65) in five of the sequences
(HLASS2 to -5). Hence, it is possible that ATM might directly
impact CS activity.
The present studies indicate that whereas the proapoptotic
effect conferred by TPA is too weak for clinical application
(50% LNCaP cell kill at 20 Gy), AS-ATM-ODN treatment
may represent an effective approach to increase radiation-
induced apoptosis in TPA-sensitive (LNCaP, CWR22-Rv1) and
TPA-resistant (PC-3, DU-145) prostate cancer cells via the CS
pathway. The significant apoptotic response observed at doses
as low as 1 and 2 Gy in AS-ATM-ODN-treated cells suggests
ATM as a potential molecular target for clinical application.
Further development of AS reagents or small molecules aimed
at ATM inactivation would appear warranted in the treatment
of prostate cancer.
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Effect of AS-ATM ODNs on ceramide levels and apoptosis
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(the time of maximal reduction in ATM protein level). Ceramide levels were measured 24 h postirradiation using the diacylglycerol kinase assay,
and apoptosis was measured 48 h postirradiation using the bisbenzimide trihydrochloride (Hoechst-33258) method as described under “Experi-
mental Procedures.” Cells were preincubated with 40 M FB1 for 3 h prior to irradiation. The percentage of inhibition with FB1 was calculated by
comparison with NT values. Results are the mean averages of duplicate samples in at least two separate experiments with S.D. shown.
Cell line Treatment Ceramide level
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ceramide levels
with FB1
Apoptosis
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of apoptosis
with FB1
pmol/106 cells % % %
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